Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new ...

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

Praxis Precision (PRAX) Triples on Stellar Drug Trial Results

We recently published Market Downturn? Not for these 10 Stocks; 7 Jump to Record Highs. Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. The offering is subject to market and other customary closing ...

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the ...